Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5203652
Max Phase: Preclinical
Molecular Formula: C143H199N27O45S2
Molecular Weight: 3080.44
Associated Items:
ID: ALA5203652
Max Phase: Preclinical
Molecular Formula: C143H199N27O45S2
Molecular Weight: 3080.44
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)COCCOCCNC(=O)c1ccc(-c2c3ccc(=O)cc-3oc3cc(O)ccc23)c(C(=O)O)c1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCCOCCOCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@@H]1CSCC(=O)CSC[C@H](NC(=O)CN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2CCC[C@H]2C(=O)N1)C(=O)NCC(N)=O
Standard InChI: InChI=1S/C143H199N27O45S2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-26-115(180)149-55-18-17-23-98(159-133(200)103(48-53-122(189)190)163-137(204)106(68-84-29-36-88(173)37-30-84)165-132(199)101(47-52-121(187)188)157-119(184)77-214-66-64-211-61-58-151-126(193)86-33-42-93(96(70-86)142(209)210)124-94-43-40-90(175)71-111(94)215-112-72-91(176)41-44-95(112)124)130(197)162-104(49-54-123(191)192)134(201)166-105(67-83-27-34-87(172)35-28-83)136(203)160-100(46-51-120(185)186)127(194)152-59-62-212-63-65-213-76-118(183)150-56-19-16-22-97(128(195)154-74-114(146)179)156-117(182)75-155-129(196)108-80-216-78-92(177)79-217-81-109(158-116(181)73-144)138(205)169-125(82(2)171)140(207)164-99(24-20-57-153-143(147)148)131(198)161-102(45-50-113(145)178)135(202)167-107(69-85-31-38-89(174)39-32-85)141(208)170-60-21-25-110(170)139(206)168-108/h27-44,70-72,82,97-110,125,171-175H,3-26,45-69,73-81,144H2,1-2H3,(H2,145,178)(H2,146,179)(H,149,180)(H,150,183)(H,151,193)(H,152,194)(H,154,195)(H,155,196)(H,156,182)(H,157,184)(H,158,181)(H,159,200)(H,160,203)(H,161,198)(H,162,197)(H,163,204)(H,164,207)(H,165,199)(H,166,201)(H,167,202)(H,168,206)(H,169,205)(H,185,186)(H,187,188)(H,189,190)(H,191,192)(H,209,210)(H4,147,148,153)/t82-,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,125+/m1/s1
Standard InChI Key: FYWPIBWNEIANCT-BZHUYTBPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3080.44 | Molecular Weight (Monoisotopic): 3078.3555 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gonschorek P, Zorzi A, Maric T, Le Jeune M, Schüttel M, Montagnon M, Gómez-Ojea R, Vollmar DP, Whitfield C, Reymond L, Carle V, Verma H, Schilling O, Hovnanian A, Heinis C.. (2022) Phage Display Selected Cyclic Peptide Inhibitors of Kallikrein-Related Peptidases 5 and 7 and Their In Vivo Delivery to the Skin., 65 (14.0): [PMID:35653695] [10.1021/acs.jmedchem.2c00306] |
Source(1):